Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

References

• Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;9(Suppl 4):14-27
   PubMedGoogle Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93
   PubMed Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64
   PubMed Web of Science ®Google Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84
   PubMed Web of Science ®Google Scholar
• Pockett RD, Castellano D, McEwan P et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010;19:755-60
   PubMed Web of Science ®Google Scholar
• Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-7
   PubMedGoogle Scholar
• Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-45
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82
   PubMed Web of Science ®Google Scholar
• Novartis. Zometa® US Prescribing Information. Novartis, East Hanover, New Jersey, USA, 2011
   Google Scholar
• Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32
   PubMed Web of Science ®Google Scholar
• Lipton A, Siena S, Rader M, et al. Comparison of denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials. Ann Oncol 2011;21:viii380, Abstract 1249P
   Google Scholar
• von Moos R, Patrick D, Fallowfield L. Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): results from a randomized phase III clinical trial. J Clin Oncol 2010;18(suppl), Abstract 9043
   Google Scholar
• Stopeck AT, Fallowfield L, Patrick D. Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: results from a phase III clinical trial. J Clin Oncol 2010;28(suppl), Abstract 1024
   PubMedGoogle Scholar
• Patrick D, Fallowfield L, Cleeland C. Effects of denosumab versus zoledronic acid on pain in patients with metastatic breast cancer: results from a randomized, double-blind, double-dummy phase 3 trial. Multinational Association of Supportive Care in Cancer Meeting, Vancouver, Canada, 2010. Abstract 274
   Google Scholar
• Fallowfield L, Patrick D, Body JJ. The effect of treatment with denosumab or zoledronic acid on health-related quality of life in patients with metastatic breast cancer. San Antonio, TX: Breast Cancer Symposium, 2010. Abstract P1-13-05
   Google Scholar
• Fallowfield L, Patrick D, Body JJ. Effect of denosumab versus zoledronic acid on health-related quality of life in patients with metastatic breast cancer. J Clin Oncol 2011;29(27 Suppl), Abstract 272
   PubMedGoogle Scholar
• Amgen Inc. Xgeva® US Prescribing Information. Amgen Inc, Thousand Oaks, CA, USA, 2010
   Google Scholar
• OECD Health Data 2011 Frequently Requested Data. Available at: http://www.oecd.org/document/16/0,3746,en_2649_37407_2085200_1_1_1_37407,00.html. Accessed July 2011
   Google Scholar
• Annemans L, Cleemput I, Simoens S. The increasing role of health economic evaluations in drug development. Drug Dev Res 2010;71:457-62
   Google Scholar
• Coleman RE. Prostate cancer: targeted therapy for prostate cancer metastases to bone. Nat Rev Urol 2011;8:296-8
   PubMedGoogle Scholar
• West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol 2011;29:1095-8
   PubMed Web of Science ®Google Scholar
• Xie J, Namjoshi M, Wu EQ, et al. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 2011;17:621-43
   PubMed Web of Science ®Google Scholar
• Rader M, Goessl C, Cong Z. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 2012;18:74-6
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
   Google Scholar
• Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006;17:1072-82
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Hirsch V, Siena S, et al. Overall survival improvement in patients with lung cancer treated with denosumab versus zoledronic acid: results from a randomized phase 3 study. 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 2011. Abstract and oral presentation O01.01
   Google Scholar
• McKeage K, Plosker GL. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics 2008;26:251-68
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;CD003474
   Google Scholar
• Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002;1:145-52
   PubMedGoogle Scholar
• Matza LS, Van Brunt K, Chung K. Health state utilities for skeletal-related events associated with bone metastases. J Clin Oncol 2011;19(suppl), Abstract e16620
   Google Scholar
• Levack P, Collie D, Gibson A, et al. A prospective audit of the diagnosis, management and outcome of malignant cord compression. CRAG Report 97/08. Edinburgh: CRAG, 2001
   Google Scholar
• United States Department of Labor. Bureau of Labor Statistics. Consumer Price Index - All Urban Consumers. US City Average, Medical Care, 12-month percent change July 2009 to July 2011. http://www.bls.gov/data. Accessed December 2011
   Google Scholar
• Analysource. Analysource Online. http://www.analysource.com. Accessed July 2011
   Google Scholar
• Ingenix. National Fee Analyzer. 50th Percentile data for CPT codes 96365 and 96372. Ingenix, Minnesota, USA, 2011
   Google Scholar
• Bell JM, Miller JD, Namjoshi M, et al. Comparative budget impact of formulary inclusion of zoledronic acid and densoumab for prevention of skeletal-related events in patients with bone metastases. Value Health 2011;14:A159
   Google Scholar
• Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res Treat 2012;131:231-8
   Google Scholar
• Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011;14:177-83
   PubMed Web of Science ®Google Scholar
• NICE. Measuring effectiveness and cost effectiveness: the QALY. http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp. Last updated April 2010, Accessed December 2011
   Google Scholar
• DesHarnais Castel L, Bajwa K, Markle JP, et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001;9:545-51
   PubMed Web of Science ®Google Scholar
• Oglesby A, Sherif B, Odom D. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Commun Oncol 2009;6:494-505
   Google Scholar
• Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
   PubMed Web of Science ®Google Scholar
• Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004;13:873-84
   PubMed Web of Science ®Google Scholar
• Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993;2:169-80
   PubMed Web of Science ®Google Scholar
• Hinz A, Klaiberg A, Brahler E, et al. [The Quality of Life Questionnaire EQ-5D: modelling and norm values for the general population]. Psychother Psychosom Med Psychol 2006;56:42-8
   PubMed Web of Science ®Google Scholar
• Kaarlola A, Pettila V, Kekki P. Performance of two measures of general health-related quality of life, the EQ-5D and the RAND-36 among critically ill patients. Intensive Care Med 2004;30:2245-52
   PubMed Web of Science ®Google Scholar
• Stein K, Fry A, Round A, et al. What value health?: a review of health state values used in early technology assessments for NICE. Appl Health Econ Health Policy 2005;4:219-28
   PubMedGoogle Scholar
• Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoecon Outcomes Res 2002;2:99-108
   PubMedGoogle Scholar
• Brazier J. Valuing health states for its use in cost-effectiveness analysis. Pharmacoeconomics 2008;26:769-79
   PubMed Web of Science ®Google Scholar
• Chambers JD, Neumann PJ, Buxton MJ. Does Medicare have an implicit cost-effectiveness threshold? Med Decis Making 2010;30:E14-E27
   PubMedGoogle Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5
   PubMed Web of Science ®Google Scholar
• Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health 2009;12:80-7
   PubMed Web of Science ®Google Scholar
• Center for the Evaluation of Risk in Health. The Cost-effectiveness Registry. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA, 2011
   Google Scholar
• Edejer T, editor. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: WHO, 2003
   Google Scholar
• Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004;171:1537–42
   PubMed Web of Science ®Google Scholar